February 2011 Editor's Picks: Products from Alfa Laval and GE Healthcare - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

February 2011 Editor's Picks: Products from Alfa Laval and GE Healthcare

Equipment and Processing Report

Featured products from Pharmaceutical Technology's monthly newsletter, Equipment & Processing Report

product Alfa Laval
Diaphragm valve provides long service life

Alfa Laval’s Unique Diaphragm Valve is designed for aseptic, ultrahygienic, and sterile processes. The valve’s actuator can be fitted with various automation and control units that feature a compact design and facilitate conversion of the control function. The actuator also permits users to adjust the spring pressure to protect the diaphragm against excessive stress. In addition, the manual valves incorporate adjustable overclosure protection. These features help to prolong the life of the diaphragm and increase uptime.

The T- and tank-outlet valves are available in block and forged versions. The forged version weighs approximately 60% less than conventional T- and tank-outlet valve bodies, according to the company. The valves’ light weight makes them quick to heat up during heat sterilization and minimizes the need for piping support of the system. Alfa Laval manufactures the valve with high-quality components, including valve bodies with low delta-ferrite content and diaphragms for continuous-steam applications.


productGE Healthcare
Chromatography media enable high throughput

GE Healthcare’s Capto SP ImpRes cation exchangers and Capto Q ImpRes anion exchangers are designed for final biopharmaceutical purification processes. The products are based on a rigid agarose matrix that enables high flow rates, thus increasing volume throughput and reducing processing times. The rigid matrix also allows personnel to use high bed heights and small column diameters that can reduce the equipment’s footprint. The products’ ability to run at high flow rates and high bed heights gives users flexibility in process design.

The media’s small bead size (~40 µm) helps users achieve high resolution. The SP and Q ligands are intended to ensure predictable performance and robust processing. The ligands also are compatible with common downstream-purification buffers and are identical to those in GE Healthcare’s other ion-exchange media. The high resolution is intended to provide high purity and high yields.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Equipment and Processing Report,
Click here